Humanigen announces preparation of Phase 1b study of ifabotuzumab in solid tumors following presentation of Phase 1 study results at EANM‘21
An abstract showing tumor specific targeting at all known tumor sites in glioblastoma patients, with no normal tissue uptake of...








